All In Biotech

Drug Trial Radar · NCT01208207

A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)

A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis

Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,015 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,015

Actual

Start

Sep 27, 2010

Primary completion

Nov 12, 2014

Study completion Nov 12, 2014

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Sep 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS). The primary objectives are to evaluate the improvement in Spinal Pain Intensity over 6 weeks of treatment with etoricoxib 90 mg or 60 mg compared to naproxen; and to evaluate the improvement in Spinal Pain Intensity over 6 weeks of treatment with etoricoxib 90 mg compared with etoricoxib 60 mg. Additionally the added benefit of increasing the dose of etoricoxib from 60 mg to 90 mg will be assessed in the second part of the study. The primary hypothesis is that the improvement in Spinal Pain Intensity visual analog scale (VAS) as measured by the time-weighted average (TWA) change from baseline over 6 weeks of treatment in Part I for etoricoxib 90 mg or 60 mg once daily is not inferior to naproxen 1000 mg.

Conditions

  • Spondylitis, Ankylosing

Interventions

  • Part I - etoricoxib 60 mgDrug

    etoricoxib 60 mg oral tablet once daily for 6 weeks

  • Part I - etoricoxib 90 mgDrug

    etoricoxib 90 mg oral tablet once daily for 6 weeks

  • Part I- naproxen 1000 mgDrug

    naproxen 500 mg oral tablet twice daily for 6 weeks

  • Part I - Placebo to naproxen 500 mgDrug

    Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks

  • Part II- etoricoxib 60 mgDrug

    etoricoxib 60 mg oral tablet once daily for 20 weeks

  • Part II- etoricoxib 90 mgDrug

    etoricoxib 90 mg oral tablet once daily for 20 weeks

  • Part II- naproxen 1000 mgDrug

    naproxen 500 mg oral tablet twice daily for 20 weeks

  • Part I - Placebo to etoricoxib 60 mgDrug

    Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.

  • Part I - Placebo to etoricoxib 90 mgDrug

    Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.

  • Part II- Placebo to etoricoxib 60 mgDrug

    Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.

  • Part II - Placebo to etoricoxib 90 mgDrug

    Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.

  • Part II- Placebo to naproxen 500 mgDrug

    Placebo to naproxen 500 mg orally twice daily for 20 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. NaproxenTime frame: Baseline and up to Week 6
  2. Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. NaproxenTime frame: Baseline and up to Week 6
  3. Number of Participants Discontinuing Study Treatment Due to an Adverse EventTime frame: Up to 26 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.